What it is
In a double-blind, placebo-controlled phase 2 trial, 507 adults with obesity were randomized to bimagrumab, semaglutide, their combination, or placebo and treated for 48 weeks. The high-dose combination of bimagrumab plus semaglutide 2.4 mg reduced body weight by 17.8 kg at week 48, versus 14.2 kg for semaglutide 2.4 mg alone, 9.3 kg for bimagrumab 30 mg/kg alone, and 3.3 kg for placebo (all significant versus placebo). Bimagrumab is an investigational antibody targeting type II activin receptors, intended to reduce total body and visceral fat while promoting muscle growth, and its common adverse events were muscle spasms, diarrhea, and acne. Improvements continued through the open-label extension to week 72.
Why it matters
Semaglutide already produces substantial weight loss on its own, but bimagrumab acts through a distinct mechanism, targeting type II activin receptors to reduce fat while promoting muscle growth. Testing them together shows whether these complementary mechanisms add to what semaglutide achieves alone.
How to read this
The extra weight loss from pairing an activin receptor antibody with semaglutide points toward multi-mechanism obesity regimens, pending larger and longer trials.
Underlined numbers link to their source. See all metrics and figures under Sources below.